ClinicalTrials.gg
RecruitingNCT07176767IPADUpdated Sep 23, 2025

The IPAD Cohort Study: Insomnia and Positive Airway Pressure Adherence in Children and Adolescents

An observational study in Sleep Apnea, Obstructive and Insomnia, sponsored by Lena Xiao. Recruiting at 1 site in Canada. Open to participants aged 8 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-09-23.

Sponsored by Lena Xiao · Observational

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
82
Ages
8 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 133 studies in Sleep Apnea, Obstructive with a site in Canada — 22 open to participants now, 31 under way, 4 of them phase 3. Sleep Apnea, Obstructive · Canada.

Planned enrollment
18th of 31
82 · median 100
Started
2025
with 9 others
Observational
31 of 133
8 open now
Primary completion
2026-12
later than 11 of 30 live
Registered
126th of 133
by date

Among the 133 studies in Sleep Apnea, Obstructive with a site in Canada, this one is the 18th largest by planned enrollment of the 31 observational ones that give a count, is one of 10 that started in 2025, is one of 31 observational ones, reaches primary completion later than 11 of the 30 other live ones, and was the 126th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

22 of the 133 studies in Sleep Apnea, Obstructive with a site in Canada are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 8 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 133 studies in Sleep Apnea, Obstructive with a site in Canada, or all of them as a file.
02

Study summary

Positive Airway Pressure (PAP) is a treatment used to help people with sleep-disordered breathing, particularly those with obstructive sleep apnea (OSA). The device delivers pressurized air through a mask to keep the airways open during sleep, improving breathing and preventing interruptions in sleep.

Studying how insomnia affects PAP adherence in children can help improve future treatments.

However, no long-term studies have looked at this in children. Based on previous research, the investigators plan to conduct a study across multiple centers focusing on children with OSA starting PAP therapy. The study will explore how insomnia affects PAP adherence and how race and ethnicity play a role.

Read the detailed description

The first line of treatment for obstructive sleep apnea (OSA) is positive airway pressure (PAP) therapy, yet children have a less than 50% adherence rate, leaving many undertreated for this condition. Insomnia has been established as a modifiable risk factor for lowering PAP therapy adherence in adults with comorbid insomnia and sleep apnea (COMISA), and research has shown that treating insomnia with cognitive behavioural therapy for insomnia (CBTi) improved PAP adherence in adults. This is an important step forward for improving COMISA treatment outcomes, but cannot yet be applied to children without researching this relationship in paediatric populations. This study will address this research gap by conducting a thorough, in-depth evaluation of the association between paediatric COMISA and PAP adherence. The investigators aim to find whether a causal relationship exists between insomnia and PAP adherence in children with OSA, which has never been assessed longitudinally in children.

This multicenter study will be conducted at two tertiary care academic hospitals: The Hospital for Sick Children (Toronto, Canada) and British Columbia Children's Hospital (BCCH) (Vancouver, Canada). This study will include 82 participants from a diverse population to assess the association between race and ethnicity with PAP therapy adherence, based on previous research showing that being part of a self-identified minority is associated with lower PAP therapy adherence. Participants and caregivers will be asked to complete questionnaires regarding insomnia, sleep behaviour and quality of life at baseline prior to PAP therapy initiation. Electronic follow up questionnaires will be administered at 1, 2, and 3 months after PAP therapy initiation and PAP download data will be completed remotely. The primary objective of this study is to evaluate the impact of baseline insomnia on PAP therapy adherence at 3 months based on self-identified racial and ethnic minority. The results of this study will provide treatment insight and improvement to children with COMISA being treated with PAP therapy.

03

Conditions studied

  • Sleep Apnea, Obstructive
  • Insomnia

Keywords

  • Obstructive Sleep Apnea
  • Insomnia
  • Pediatric Sleep
  • Positive Airway Pressure Adherence
04

Who can participate

Ages eligible
8 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants will be recruited from two tertiary care academic hospitals, The Hospital for Sick Children (Toronto, Canada) and British Columbia Children's Hospital (BCCH) (Vancouver, Canada).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Children aged 8-18 years old
  2. Obstructive apnea-hypopnea index ≥ 5/hour on baseline diagnostic polysomnogram (PSG)
  3. Newly prescribed PAP therapy

Exclusion criteria

Exclusion Criteria:

1) Developmental disability precluding ability to answer questionnaires

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
82 participants (estimated)
Patient registry
No

Groups and cohorts

  • OSA Children Starting PAP

    Children aged 8-18 years old diagnosed with obstructive sleep apnea (OSA) who are to be initiated on Positive Airway Pressure (PAP) therapy. Children and their caregivers must be willing and able to complete questionnaires about sleep as well as physical and mental health.

    Device: Positive airway pressure therapy

Interventions

  • DevicePositive airway pressure therapy

    Initiation of continuous or bilevel positive airway pressure therapy

    Also known as: Continuous positive airway pressure therapy, Bilevel positive airway pressure therapy

06

What researchers measure

Primary outcomes

  1. Mean minutes of nightly PAP usage

    Adherence will be determined objectively using ventilator download data (days 60-90 after PAP initiation)

    Time frame: 90 days

Secondary outcomes

  1. Mean minutes of nightly PAP usage

    Adherence will be determined objectively using ventilator download data (days 0-30 and 30-60 after PAP initiation)

    Time frame: 30, 60 days

  2. Self-Reported Sense of Mastery (Caregiver)

    The self-reported Pearlin Mastery Scale will be used to measure the caregiver's mastery. Scores range from 7 to 28, with higher scores indicating greater levels of mastery.

    Time frame: 0, 90 days

  3. Self-Reported Sense of Mastery (Participant)

    The self-reported Pearlin Mastery Scale will be used to measure the participant's individual mastery. Scores range from 7 to 28, with higher scores indicating greater levels of mastery.

    Time frame: 0, 90 days

  4. Self-Reported Psychological Scale (Percentage Rank)

    The self-reported Psychological Scale from the KIDSCREEN-10 questionnaire will be used to measure health-related quality of life. The score ranges from 10-50, with lower scores indicating a "dissatisfaction with life".

    Time frame: 0, 90 days

  5. Self-Reported Psychological Scale

    The self-reported Psychological Scale from the Strengths and Difficulties questionnaire will be used. Scores range from 0-50 with higher scores indicating more difficulties and lower scores indicating more strengths.

    Time frame: 0, 90 days

  6. Self-Reported Sleep Diary

    The self-reported National Institutes of Health (NIH) 1-week Sleep Diary will be used to record the quality and quantity of sleep.

    Time frame: 0, 90 days

  7. Caregiver-Reported Insomnia Questionnaire

    The caregiver-reported Pediatric Insomnia Severity Index will be used to measure the severity of pediatric insomnia symptoms. Scores range from 0 to 30, with higher scores indicating greater insomnia severity.

    Time frame: 0, 90 days

  8. Self-Reported Insomnia Questionnaire (Participant)

    The self-reported Insomnia Severity Index will be used to measure the nature, severity and impact of the participant's insomnia. Scores range from 0 to 28, with higher scores indicating greater insomnia severity.

    Time frame: 0, 30, 60, 90 days

  9. Self-Reported Insomnia Questionnaire (Participant)

    The self-reported Insomnia Severity Index will be used to diagnose insomnia in the participant. Children will be classified as having insomnia using a cut-off of ≥ 9 points, based on the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition.

    Time frame: 0, 30, 60, 90 days

  10. Self-Reported Insomnia Questionnaire (Caregiver)

    The self-reported Insomnia Severity Index will be used to measure the nature, severity and impact of the caregiver's insomnia. Scores range from 0 to 28, with higher scores indicating greater insomnia severity.

    Time frame: 0, 90 days

  11. Self-Reported Insomnia Questionnaire (Caregiver)

    The self-reported Insomnia Severity Index will be used to diagnose insomnia in the caregiver. Caregiver's will be classified as having insomnia using a cut-off of ≥ 9 points, based on the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition.

    Time frame: 0, 90 days

  12. Self-Reported Chronotype Questionnaire

    The self-reported Munich Chronotype Questionnaire will be used to measure participant chronotype. Scores range from 16 to 86 with scores below 42 indicating "evening types", scores between 42-58 indicating "intermediate types" and scores above 58 indicating "morning types".

    Time frame: 0, 90 days

  13. Self-Reported Chronotype Questionnaire

    The self-reported Morningness/Eveningness Questionnaire will be used to measure differences in activeness and alertness in the mornings and evenings. Scores range from 16 to 86, with lower scores representing evening preference and higher scores representing morning preference.

    Time frame: 0, 90 days

  14. Caregiver's Self-Reported Chronotype Questionnaire

    The self-reported Morningness/Eveningness Questionnaire will be used to measure the caregiver's differences in activeness and alertness in the mornings and evenings. Scores range from 16 to 86, with lower scores representing evening preference and higher scores representing morning preference.

    Time frame: 0, 90 days

  15. Self-Reported Daytime Sleepiness Questionnaire

    The self-reported Epworth Sleepiness Scale will be used to measure daytime sleepiness. Scores range from 0-24 with lower score indicating less daytime sleepiness.

    Time frame: 0, 90 days

  16. Self-Reported Caffeine Intake Questionnaire

    The self-reported Caffeine Consumption Questionnaire-Revised will be used to measure weekly caffeine intake. The quantity and frequency of caffeinated products reported is used to estimate the average daily caffeine consumption in mg.

    Time frame: 0, 90 days

  17. Self-Reported Sleep Hygiene Questionnaire

    The self-reported Adolescent Sleep Hygiene Scale (ASHS) will be used to assess sleep habits and hygiene practices. The 33-item scale contains 28 quantitative items, which are scored as the following: never (0%) = 1; once in a while (20%) = 2; sometimes (40%) = 3; quite often (60%) = 4; frequently, if not always (80%) = 5; always (100%) = 6. Total scores range from 28-168, with higher scores indicating greater sleep hygiene.

    Time frame: 0, 90 days

  18. Caregiver-Reported Global Rating Scale of Change

    The caregiver-reported Global Rating Scale of Change will be used to measure the caregiver's perceived improvement or deterioration of the child's quality of life over time. The scale ranges from -7 to +7, with greater scores indicating improvements in quality of life.

    Time frame: 90 days

  19. Self-Reported Global Rating Scale of Change

    The self-reported Global Rating Scale of Change will be used to measure the participant's perceived improvement or deterioration of their quality of life over time. The scale ranges from -7 to +7, with greater scores indicating improvements in quality of life.

    Time frame: 90 days

  20. Self-Reported PAP Adherence Questionnaire

    The self-reported Adherence Barriers to CPAP Questionnaire will be used to estimate the participant's success or failure to use their PAP. The score ranges from 31 to 155, with greater scores indicating a higher number and severity of CPAP barriers.

    Time frame: 90 days

  21. Self-Reported Psychological (Total Anxiety) Subscale

    The self-reported Total Anxiety Subscale (major outcome) from the Revised Child Anxiety and Depression Scale will be used. The raw score from the subscale, which ranges from 0-45, will be used to calculate the T score by taking into consideration development level and gender. A T score of 65 or higher indicates a score borderline the clinical threshold and a T score of 70 or higher indicates a score above the clinical threshold.

    Time frame: 0, 90 days

  22. Self-Reported Psychological (Total Depression) Scale

    The self-reported Total Depression (major outcome) from the Revised Child Anxiety and Depression Scale will be used. The raw score from the subscale, which ranges from 0-30, will be used to calculate the T score by taking into consideration development level and gender. A T score of 65 or higher indicates a score borderline the clinical threshold and a T score of 70 or higher indicates a score above the clinical threshold.

    Time frame: 0, 90 days

  23. Self-Reported Psychological (Social Phobia) Scale

    The self-reported Social Phobia Subscale (major outcome) from the Revised Child Anxiety and Depression Scale will be used. The raw score from the subscale, which ranges from 0-27, will be used to calculate the T score by taking into consideration development level and gender. A T score of 65 or higher indicates a score borderline the clinical threshold and a T score of 70 or higher indicates a score above the clinical threshold.

    Time frame: 0, 90 days

  24. Self-Reported Psychological (Panic Disorder) Scale

    The self-reported Panic Disorder Subscale (major outcome) from the Revised Child Anxiety and Depression Scale will be used. The raw score from the subscale, which ranges from 0-27, will be used to calculate the T score by taking into consideration development level and gender. A T score of 65 or higher indicates a score borderline the clinical threshold and a T score of 70 or higher indicates a score above the clinical threshold.

    Time frame: 0, 90 days

  25. Self-Reported Psychological (Major Depression) Scale

    The self-reported Major Depression Subscale (major outcome) from the Revised Child Anxiety and Depression Scale will be used. The raw score from the subscale, which ranges from 0-30, will be used to calculate the T score by taking into consideration development level and gender. A T score of 65 or higher indicates a score borderline the clinical threshold and a T score of 70 or higher indicates a score above the clinical threshold.

    Time frame: 0, 90 days

  26. Self-Reported Psychological (Separation Anxiety) Scale

    The self-reported Separation Anxiety Subscale (major outcome) from the Revised Child Anxiety and Depression Scale will be used. The raw score from the subscale, which ranges from 0-21, will be used to calculate the T score by taking into consideration development level and gender. A T score of 65 or higher indicates a score borderline the clinical threshold and a T score of 70 or higher indicates a score above the clinical threshold.

    Time frame: 0, 90 days

  27. Self-Reported Psychological (Generalized Anxiety) Scale

    The self-reported Generalized Anxiety Subscale (major outcome) from the Revised Child Anxiety and Depression Scale will be used. The raw score from the subscale, which ranges from 0-18, will be used to calculate the T score by taking into consideration development level and gender. A T score of 65 or higher indicates a score borderline the clinical threshold and a T score of 70 or higher indicates a score above the clinical threshold.

    Time frame: 0, 90 days

  28. Self-Reported Psychological (Obsessive-Compulsive) Scale

    The self-reported Obsessive-Compulsive Subscale (major outcome) from the Revised Child Anxiety and Depression Scale will be used. The raw score from the subscale, which ranges from 0-18, will be used to calculate the T score by taking into consideration development level and gender. A T score of 65 or higher indicates a score borderline the clinical threshold and a T score of 70 or higher indicates a score above the clinical threshold.

    Time frame: 0, 90 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.

Of 258 non-industry observational studies under Sleep Apnea, Obstructive, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 63. This study's planned 18 months is below that.

Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 14 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2025
First posted
Sep 16, 2025
StartActual
Jun 12, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Sep 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07176767
Lead sponsor
Lena Xiao
Collaborators
American Academy of Sleep Medicine, The Hospital for Sick Children
Responsible party
Lena Xiao (Clinical Assistant Professor, University of British Columbia) — Sponsor-investigator
First posted
Sep 16, 2025
Start date
Jun 12, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 23, 2025

Study contacts

Lena J Xiao, MD MSc
Contact
lena.xiao@cw.bc.ca
6048752345 ext. 7606
Macyn LY Leung, MSc
Contact
macyn.leung@bcchr.ca
6048752345 ext. 7606
Lena J Xiao, MD, MSc
principal investigator · Provincial Health Services Authority British Columbia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion